Tag: Blenrep
Belantamab Mafodotin to be Withdrawn from US-market
GSK has initiated the process for withdrawal of belantamab mafodotin-blmf (Blenrep®) from the US market. The withdrawal of the US marketing authorization follows the request of the US Food and Drug Administration (FDA).
ASH 2020: Potential of Belantamab Mafodotin in Combination Standard Therapies in...
Multiple myeloma is the second most common hematological malignancy in the United States and is generally considered treatable, but not curable. Multiple myeloma...
European Commission Grants Conditional Marketing Authorization to GSK for the Use...
The European Commission has granted conditional marketing authorization* for the use of GlaxoSmithKline's anti-B-cell maturation antigen (BCMA) therapy belantamab mafodotin (Blenrep®) as monotherapy for...
U.S. FDA Approves Belantamab Mafodotin as a Monotherapy in R/R Multiple...
The U.S. Food and Drug Administration has approved* belantamab mafodotin-blmf (Blenrep®; GlaxoSmithKline/GSK) as a monotherapy treatment for adult patients with relapsed or refractory multiple...
